Biomarker conservation in primary and metastatic epithelial ovarian cancer

Gynecologic Oncology

Volumn 78, Issue 2, 2000, Pages 130-136

  Tewari, Krishnansu Sujata ^a   Kyshtoobayeva, Ainura S ^b   Mehta, Rita S ^a,b   Yu, Ing Ru ^b   Burger, Robert A ^a   DiSaia, Philip J ^a   Fruehauf, John P ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Oncotech Inc   (United States)

Author keywords

Angiogenesis; Biologic prognostic factors; Biomarkers; Clonal divergence; Ovarian cancer; Tumor heterogeneity

Indexed keywords

CD31 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; MULTIDRUG RESISTANCE PROTEIN; ONCOPROTEIN; PROTEIN P53; TUMOR MARKER;

ADULT; ANEUPLOIDY; ARTICLE; CELL CYCLE S PHASE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0033846715     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2000.5837     Document Type: Article

References (29)

1. Prognostic factors in ovarian cancer
2. The molecular basis of ovarian cancer
3. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate
4. Rationale for the use of alternating non-cross-resistant chemotherapy
5. The genetic basis of resistance to cancer chemotherapy
6. Zu frage der erstehung maligner tumoren
7. Chromosome studies on normal and leukemic human leukocytes
8. Genetic alterations in cancer cells
9. X-chromosome inactivation and development patterns in mammals
10. Clonal origin of epithelial ovarian carcinoma: Analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation
11. Molecular genetic evidence for unifocal origin of advanced epithelial ovarian cancer and for minor clonal divergence
12. Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer
13. The clonal evolution of tumor cell populations
14. Minimizing drug resistance: The somatic mutation model and gestational trophoblastic neoplasia
15. Ovarian carcinoma heterogeneity as demonstrated by DNA ploidy
16. Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma
17. Intratumor heterogeneity of morphometric and steriologic variables in primary ovarian tumors and their omental metastatic deposits
18. Detection of cellular heterogeneity by DNA ploidy, 17 chromosome, and p53 gene in primary carcinoma and metastasis in a case of ovarian cancer
19. p53 expression, DNA content and cell proliferation in primary and synchronous metastatic lesions from ovarian surface epithelial-stromal tumours
20. Flow cytometric analysis of lymph node metastases in advanced ovarian cancer: Clinical and biologic significance
21. Chemotherapy changes the DNA ploidy in ovarian cancer
22. Concordance of DNA ploidy pattern as measured by flow cytometry in primary, metastatic, and persistent ovarian carcinoma
23. Immunophenotype of ovarian cancer as predictor of clinical outcome: Evaluation at primary surgery and second-look procedure
24. DNA index reflects the biological behavior of ovarian carcinoma Stage I-IIa
25. Vascular permeability factor gene expression in normal and neoplastic human ovaries
26. The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer
27. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas
28. Tumor angiogenesis in advanced stage ovarian carcinoma
29. Overexpression and relationships of HER2, epidermal growth factor receptor, Ki67, and tumor necrosis factor alpha in epithelial ovarian cancer